Saol Therapeutics announces acceptance of New Drug Application
ROSWELL, Ga, DUBLIN and HAMILTON, Bermuda, Jan. 28, 2025 — Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SL1009, Sodium Dichloroacetate Oral Solution (DCA). DCA will be used with a proprietary genetic test to treat an orphan pediatric mitochondrial disease, Pyruvate… Read more »